Search

Your search keyword '"Grimaldi, L. M. E."' showing total 19 results

Search Constraints

Start Over You searched for: Author "Grimaldi, L. M. E." Remove constraint Author: "Grimaldi, L. M. E." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
19 results on '"Grimaldi, L. M. E."'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

3. Signs and symptoms of COVID-19 in patients with multiple sclerosis

4. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

5. Signs and symptoms of COVID-19 in patients with multiple sclerosis

6. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

7. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

8. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

9. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

10. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study

11. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

12. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

13. The Italian multiple sclerosis register

14. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

15. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

16. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

17. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

18. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

19. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

Catalog

Books, media, physical & digital resources